1. Home
  2. MGNX vs BLZE Comparison

MGNX vs BLZE Comparison

Compare MGNX & BLZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.15

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Logo Backblaze Inc.

BLZE

Backblaze Inc.

HOLD

Current Price

$7.56

Market Cap

218.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
BLZE
Founded
2000
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
220.6M
218.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
MGNX
BLZE
Price
$3.15
$7.56
Analyst Decision
Buy
Buy
Analyst Count
5
6
Target Price
$5.00
$7.60
AVG Volume (30 Days)
715.2K
459.7K
Earning Date
05-08-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.56
EPS
N/A
N/A
Revenue
$149,500,000.00
$145,835,000.00
Revenue This Year
N/A
$10.16
Revenue Next Year
$3.19
$10.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.27
52 Week Low
$1.19
$3.26
52 Week High
$3.88
$10.86

Technical Indicators

Market Signals
Indicator
MGNX
BLZE
Relative Strength Index (RSI) 50.69 91.56
Support Level $1.45 $7.35
Resistance Level $3.26 $8.16
Average True Range (ATR) 0.19 0.27
MACD -0.05 0.25
Stochastic Oscillator 33.55 82.08

Price Performance

Historical Comparison
MGNX
BLZE

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

About BLZE Backblaze Inc.

Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.

Share on Social Networks: